IGC Stock Summary and Trading Ideas (Igc Pharma | AMEX:IGC)

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Igc Pharma trades on the AMEX stock market under the symbol IGC.

As of March 27, 2026, IGC stock price declined to $0.26 with 264,457 million shares trading.

IGC has a beta of 0.61, meaning it tends to be less sensitive to market movements. IGC has a correlation of 0.04 to the broad based SPY ETF.

IGC has a market cap of $25.22 million. This is considered a Sub-Micro Cap stock.

Last quarter Igc Pharma reported $213,000 in Revenue and -$.01 earnings per share. This fell short of revenue expectation by $-179,100 and exceeded earnings estimates by $.01.

In the last 3 years, IGC traded as high as $.91 and as low as $.24.

The top ETF exchange traded funds that IGC belongs to (by Net Assets): VXF.

IGC has underperformed the market in the last year with a price return of -14.9% while the SPY ETF gained +13.1%. IGC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.9% and -9.8%, respectively, while the SPY returned -7.9% and -4.0%, respectively.

IGC support price is $.25 and resistance is $.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IGC shares will trade within this expected range on the day.